Enrollment Complete for Cannabinoid MS Study

The Peninsula Medical School has enrolled the full cohort for its Phase III CUPID trial using a cannabis ingredient as a treatment for multiple sclerosis (MS).

Current MS treatments either target the immune system in the early stages of the disease or try to ease symptoms such as muscle spasms or bladder problems. The new study in 493 people will evaluate whether tetrahydrocannabinol (THC), the main active ingredient in the cannabis plant, is able to slow progression of the disease.

Results from the UK study are expected by spring or early summer of 2012, the medical school said.